Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
Lurleen Wallace Comprehensive Cancer at University of Alabama-Birmingham National Cancer Institute (NCI) |
---|---|
Information provided by: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT00003556 |
RATIONALE: Vaccines may make the body build an immune response that may kill tumor cells. Combining more than one vaccine may kill more tumor cells.
PURPOSE: Phase I trial to study the effectiveness of vaccine therapy in treating patients with melanoma that cannot be treated with surgery.
Condition | Intervention | Phase |
---|---|---|
Melanoma (Skin) |
Biological: ALVAC-hB7.1 Biological: canarypox-hIL-12 melanoma vaccine |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment |
Official Title: | Phase Ib Trial of Intratumoral Injection of a Recombinant Canarypox Virus Encoding Human B7.1 (ALVAC-hB7.1) or a Combination of ALVAC-hB7.1 and a Recombinant Canarypox Virus Encoding Human Interleukin 12 (ALVAC-hIL-12) in Patients With Surgically Incurable Melanoma |
Estimated Enrollment: | 15 |
Study Start Date: | January 1999 |
OBJECTIVES: I. Determine the toxic effects associated with ALVAC-hB7.1 alone or combined with ALVAC-hIL-12 in patients with surgically incurable melanoma. II. Characterize the inflammatory and lymphokine response to this regimen in these patients. III. Examine the extent of nodule regression, humoral immune response, and cytolytic T cell activity with this regimen in these patients.
OUTLINE: This is a dose escalation study of ALVAC-hB7.1 Patients receive ALVAC-hB7.1 alone or combined with ALVAC-hIL-12 intratumorally on days 1, 4, 8, and 11. Treatment continues in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients are treated at each dose level of ALVAC-hB7.1. The maximum tolerated dose is defined as the dose of ALVAC-hB7.1 at which no more than 1 of 5 patients experiences dose limiting toxicity.
Patients are followed at 1, 2, 4, 8, 11, 15, 22, and 43 days after the first vaccination.
PROJECTED ACCRUAL: Approximately 15 patients will be accrued for this study within 18 months.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS: Histologically confirmed melanoma that is surgically incurable At least one dermal, subcutaneous or lymph node metastasis that is evaluable for local response and accessible for injection If only one accessible lesion is available, it must be at least 2 cm If two or more accessible lesions exist, then none of them are required to be at least 2 cm
PATIENT CHARACTERISTICS: Age: Over 18 Performance status: ECOG 0-2 Life expectancy: Greater than 3 months Hematopoietic: Leukocyte count at least 3,000/mm3 Platelet count at least 120,000/mm3 Hepatic: SGOT and alkaline phosphatase less than 5 times normal Bilirubin less than 1.5 mg/dL (unless secondary to hepatic metastasis) Renal: BUN less than 40 mg/dL Creatinine less than 2.5 mg/dL Cardiovascular: No evidence of congestive heart failure, unstable angina, or serious cardiac arrhythmias Other: Not positive for hepatitis B virus Not positive for HIV No history of allergy to vaccinia virus No evidence of other primary tumors except for basal cell carcinoma, squamous cell skin carcinoma, or carcinoma in situ of the cervix Not pregnant or nursing Fertile patients must use effective contraception No underlying immunodeficiency disorder
PRIOR CONCURRENT THERAPY: Biologic therapy: At least 30 days since prior biologic therapy (e.g., interferon or IL-2) Chemotherapy: At least 30 days since prior chemotherapy Endocrine therapy: No concurrent steroids Radiotherapy: At least 30 days since prior radiotherapy Prior radiotherapy to no greater than 50% of nodal groups Surgery: See Disease Characteristics No prior splenectomy Other: No concurrent drugs which affect immune function (e.g., glucocorticoids or cimetidine)
United States, Alabama | |
University of Alabama Comprehensive Cancer Center | |
Birmingham, Alabama, United States, 35294 |
Study Chair: | Robert M. Conry, MD | Lurleen Wallace Comprehensive Cancer at University of Alabama-Birmingham |
Study ID Numbers: | CDR0000066619, UAB-9705, NCI-T97-0046 |
Study First Received: | November 1, 1999 |
Last Updated: | February 6, 2009 |
ClinicalTrials.gov Identifier: | NCT00003556 History of Changes |
Health Authority: | United States: Federal Government |
stage IV melanoma recurrent melanoma |
Virus Diseases Neuroectodermal Tumors Interleukin-12 Nevus, Pigmented Neoplasms, Germ Cell and Embryonal |
Neuroepithelioma Nevus Recurrence Neuroendocrine Tumors Melanoma |
Neuroectodermal Tumors Neoplasms Neoplasms by Histologic Type Neoplasms, Germ Cell and Embryonal |
Neoplasms, Nerve Tissue Nevi and Melanomas Neuroendocrine Tumors Melanoma |